RamanProject reference: 332462
Funded under :
Gold Nanoprisms as Raman Signal Amplifiers for Bioimaging of Lung Cancer
Total cost:EUR 254 637,8
EU contribution:EUR 254 637,8
Topic(s):FP7-PEOPLE-2012-IEF - Marie-Curie Action: "Intra-European fellowships for career development"
Call for proposal:FP7-PEOPLE-2012-IEFSee other projects for this call
Funding scheme:MC-IEF - Intra-European Fellowships (IEF)
Raman spectroscopy is a powerful tool for probing biochemical changes in situ at tissue level. The vibrational profile can provide invaluable molecular details for medical diagnosis and disease prognosis. Important technological as well as health and safety considerations, however, limits its clinical application, as spontaneous Raman is a relatively weak effect and high laser powers are required for rapid screening. Surface-enhanced Raman scattering (SERS) makes is possible to probe single molecules adsorbed onto a silver or gold nanoparticle, greatly enhancing the sensitivity of spontaneous Raman and therefore potentially significantly reducing screening times. However, the SERS sensitivity from spherical gold nanoparticles is still insufficient to detect trace biomolecules and/or the interaction between biomolecules, which may be overcome through using novel shape nanomaterials as SERS substrates for the improvement of the bio-detection limit. Recently, Pegylated gold nanoprisms (AuNPrs) have been successfully employed as signal amplifiers in multimodal in vivo imaging of cancer cells, and therefore pose a great potential for Raman spectroscopy as well. Excellent biocompatibility properties are known for Pegylated AuNPrs, with side lengths of 120nm and thicknesses of 10nm. They absorb strongly at a wavelength of 830 nm, with co-efficients of up to 37 µg.mL-1•OD-1, a wavelength within the tissue transparency window, promising deep penetration in vivo This project will explore the optimisation of Pegylated AuNPrs for surface enhancement of the Raman signal (SERS)of their local cellular environment for probing disease in vitro and ulimately in vivo. Lung cancer is the most common cause of death from cancer in the EU and is therefore chosen as a model for the development of a Raman based rapid screening technique for early detection of disease.
EU contribution: EUR 254 637,8
RATHMINES ROAD LOWER 143-149
Tel.: +353 1 4023370